Skip to content
← Full study record

NCT04173494 · MORE INFO

Limitations, agreements, and source contact

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) · Source last updated 2023-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
GlaxoSmithKline (GSK) agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
GSKClinicalSupportHD@gsk.com
organization
Sierra Oncology LLC - a GSK company
phone
866-435-7343
title
GSK Response Center
Complete source fields
certain Agreement
other Details
GlaxoSmithKline (GSK) agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
GSKClinicalSupportHD@gsk.com
organization
Sierra Oncology LLC - a GSK company
phone
866-435-7343
title
GSK Response Center

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice